The suit claims Wyeth Pharmaceuticals, part of Pfizer, marketed the immunosuppressive drug, Rapamune, for use in other transplant patients, a use not approved by the Food and Drug Administration. Furthermore, Wyeth allegedly instructed its sales staff to use financial incentives to encourage the drug’s use in non-kidney transplant patients.
“FDA’s drug approval process ensures companies market their products for uses proven safe and effective,” said Stuart F. Delery, acting assistant attorney general for the Justice Department’s Civil Division, in the Department of Justice release. “We will hold accountable those who put patients’ health at risk in pursuit of financial gain.”
More Articles on Settlements:
Beth Israel Deaconess to Pay $5.3M in False Claims Settlement
WellPoint to Pay $1.7M Over Alleged HIPAA Violations
Allegiance Health to Pay $1.8M in False Claims Settlement
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
